Clinical trials to test employment drugs to manipulate mGluR1 have yielded limited results for treatment of epilepsy, pain, Alzheimer’s, Parkinson’s, anxiety/depression (Hovelsø et al., 2012). Here, GRM1 is linked to epilepsy.